RepliCel Cost Of Revenue vs Income Tax Expense Analysis

RP Stock

CAD 0.01 0.01 33.33%

RepliCel Life financial indicator trend analysis is much more than just breaking down RepliCel Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RepliCel Life Sciences is a good investment. Please check the relationship between RepliCel Life Cost Of Revenue and its Income Tax Expense accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Cost Of Revenue vs Income Tax Expense

Cost Of Revenue vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RepliCel Life Sciences Cost Of Revenue account and Income Tax Expense. At this time, the significance of the direction appears to have no relationship.

The correlation between RepliCel Life's Cost Of Revenue and Income Tax Expense is 0.02. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of RepliCel Life Sciences, assuming nothing else is changed. The correlation between historical values of RepliCel Life's Cost Of Revenue and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of RepliCel Life Sciences are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Cost Of Revenue i.e., RepliCel Life's Cost Of Revenue and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

0.02

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on RepliCel Life Sciences income statement and represents the costs associated with goods and services RepliCel Life provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Tax Expense

Most indicators from RepliCel Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RepliCel Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, RepliCel Life's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 5.46 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.54) in 2024.

RepliCel Life fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Non Currrent Assets Other	Other Assets	Non Current Liabilities Total	Other Current Assets	Other Liab	Net Tangible Assets	Property Plant Equipment
Total Assets		0.19	-0.19	0.49	0.34	-0.81	0.12	-0.15	0.81	0.0	0.98	0.3	-0.29	0.41	-0.22	0.99	-0.53	0.02	0.58	-0.31	0.33	-0.31	0.13	-0.23	0.34	0.19
Short Long Term Debt Total	0.19		-0.14	0.35	0.2	0.04	0.06	-0.29	0.15	-0.25	0.22	-0.21	0.15	0.29	-0.31	0.22	-0.17	-0.04	0.41	-0.4	-0.09	-0.55	0.26	0.05	0.2	0.11
Total Current Liabilities	-0.19	-0.14		-0.87	-0.87	0.3	-0.95	0.71	-0.16	0.8	-0.35	0.65	0.82	-0.34	0.91	-0.28	0.7	0.88	-0.39	-0.4	0.3	0.68	-0.44	0.85	-0.94	-0.95
Total Stockholder Equity	0.49	0.35	-0.87		0.87	-0.49	0.84	-0.51	0.39	-0.77	0.61	-0.47	-0.77	0.37	-0.96	0.57	-0.88	-0.73	0.7	0.17	-0.1	-0.88	0.52	-0.76	0.97	0.87
Property Plant And Equipment Net	0.34	0.2	-0.87	0.87		-0.43	0.88	-0.4	0.27	-0.73	0.48	-0.5	-0.86	0.57	-0.87	0.41	-0.84	-0.79	0.65	0.05	-0.17	-0.8	0.6	-0.84	0.9	0.95
Net Debt	-0.81	0.04	0.3	-0.49	-0.43		-0.34	0.08	-0.95	0.08	-0.8	-0.14	0.48	-0.28	0.29	-0.81	0.62	0.19	-0.66	0.14	-0.27	0.28	-0.11	0.43	-0.42	-0.34
Retained Earnings	0.12	0.06	-0.95	0.84	0.88	-0.34		-0.58	0.19	-0.75	0.28	-0.68	-0.85	0.32	-0.9	0.2	-0.73	-0.94	0.44	0.4	-0.32	-0.68	0.37	-0.92	0.93	0.97
Accounts Payable	-0.15	-0.29	0.71	-0.51	-0.4	0.08	-0.58		-0.13	0.52	-0.27	0.56	0.27	-0.23	0.52	-0.2	0.14	0.61	0.02	-0.45	0.53	0.27	0.03	0.41	-0.51	-0.54
Cash	0.81	0.15	-0.16	0.39	0.27	-0.95	0.19	-0.13		0.04	0.79	0.13	-0.23	0.29	-0.16	0.8	-0.45	-0.09	0.61	-0.21	0.22	-0.22	-0.03	-0.26	0.27	0.18
Non Current Assets Total	0.0	-0.25	0.8	-0.77	-0.73	0.08	-0.75	0.52	0.04		-0.16	0.61	0.55	-0.26	0.86	-0.1	0.58	0.74	-0.43	-0.27	0.51	0.76	-0.6	0.53	-0.78	-0.79
Cash And Short Term Investments	0.98	0.22	-0.35	0.61	0.48	-0.8	0.28	-0.27	0.79	-0.16		0.14	-0.38	0.52	-0.36	0.99	-0.59	-0.15	0.61	-0.24	0.18	-0.41	0.2	-0.36	0.47	0.35
Net Receivables	0.3	-0.21	0.65	-0.47	-0.5	-0.14	-0.68	0.56	0.13	0.61	0.14		0.35	-0.13	0.62	0.23	0.2	0.75	-0.04	-0.56	0.51	0.4	-0.05	0.52	-0.53	-0.66
Common Stock Shares Outstanding	-0.29	0.15	0.82	-0.77	-0.86	0.48	-0.85	0.27	-0.23	0.55	-0.38	0.35		-0.22	0.79	-0.35	0.86	0.69	-0.48	-0.26	-0.11	0.58	-0.48	0.88	-0.87	-0.87
Other Stockholder Equity	0.41	0.29	-0.34	0.37	0.57	-0.28	0.32	-0.23	0.29	-0.26	0.52	-0.13	-0.22		-0.28	0.43	-0.31	-0.32	0.44	-0.41	-0.3	-0.41	0.38	-0.43	0.33	0.43
Total Liab	-0.22	-0.31	0.91	-0.96	-0.87	0.29	-0.9	0.52	-0.16	0.86	-0.36	0.62	0.79	-0.28		-0.3	0.82	0.82	-0.59	-0.29	0.21	0.88	-0.54	0.79	-0.98	-0.92
Total Current Assets	0.99	0.22	-0.28	0.57	0.41	-0.81	0.2	-0.2	0.8	-0.1	0.99	0.23	-0.35	0.43	-0.3		-0.58	-0.06	0.63	-0.28	0.28	-0.39	0.19	-0.28	0.42	0.27
Short Term Debt	-0.53	-0.17	0.7	-0.88	-0.84	0.62	-0.73	0.14	-0.45	0.58	-0.59	0.2	0.86	-0.31	0.82	-0.58		0.56	-0.84	0.05	-0.24	0.82	-0.59	0.74	-0.88	-0.77
Common Stock	0.02	-0.04	0.88	-0.73	-0.79	0.19	-0.94	0.61	-0.09	0.74	-0.15	0.75	0.69	-0.32	0.82	-0.06	0.56		-0.33	-0.43	0.47	0.62	-0.29	0.82	-0.82	-0.91
Other Current Liab	0.58	0.41	-0.39	0.7	0.65	-0.66	0.44	0.02	0.61	-0.43	0.61	-0.04	-0.48	0.44	-0.59	0.63	-0.84	-0.33		-0.41	0.2	-0.79	0.55	-0.44	0.61	0.5
Non Currrent Assets Other	-0.31	-0.4	-0.4	0.17	0.05	0.14	0.4	-0.45	-0.21	-0.27	-0.24	-0.56	-0.26	-0.41	-0.29	-0.28	0.05	-0.43	-0.41		-0.3	0.15	-0.39	-0.34	0.28	0.31
Other Assets	0.33	-0.09	0.3	-0.1	-0.17	-0.27	-0.32	0.53	0.22	0.51	0.18	0.51	-0.11	-0.3	0.21	0.28	-0.24	0.47	0.2	-0.3		0.1	0.05	0.13	-0.11	-0.31
Non Current Liabilities Total	-0.31	-0.55	0.68	-0.88	-0.8	0.28	-0.68	0.27	-0.22	0.76	-0.41	0.4	0.58	-0.41	0.88	-0.39	0.82	0.62	-0.79	0.15	0.1		-0.71	0.57	-0.83	-0.74
Other Current Assets	0.13	0.26	-0.44	0.52	0.6	-0.11	0.37	0.03	-0.03	-0.6	0.2	-0.05	-0.48	0.38	-0.54	0.19	-0.59	-0.29	0.55	-0.39	0.05	-0.71		-0.32	0.52	0.45
Other Liab	-0.23	0.05	0.85	-0.76	-0.84	0.43	-0.92	0.41	-0.26	0.53	-0.36	0.52	0.88	-0.43	0.79	-0.28	0.74	0.82	-0.44	-0.34	0.13	0.57	-0.32		-0.87	-0.89
Net Tangible Assets	0.34	0.2	-0.94	0.97	0.9	-0.42	0.93	-0.51	0.27	-0.78	0.47	-0.53	-0.87	0.33	-0.98	0.42	-0.88	-0.82	0.61	0.28	-0.11	-0.83	0.52	-0.87		0.94
Property Plant Equipment	0.19	0.11	-0.95	0.87	0.95	-0.34	0.97	-0.54	0.18	-0.79	0.35	-0.66	-0.87	0.43	-0.92	0.27	-0.77	-0.91	0.5	0.31	-0.31	-0.74	0.45	-0.89	0.94

Click cells to compare fundamentals

RepliCel Life Account Relationship Matchups

RepliCel Life fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	505.5K	421.0K	591.8K	798.2K	287.8K	273.4K
Total Current Liabilities	1.6M	2.2M	1.7M	2.1M	1.8M	1.9M
Total Stockholder Equity	(4.4M)	(5.1M)	(6.8M)	(5.9M)	(4.5M)	(4.3M)
Property Plant And Equipment Net	6.0K	4.4K	3.3K	2.4K	967.0	918.65
Net Debt	425.4K	41.7K	(186.9K)	(372.1K)	754.0K	791.7K
Retained Earnings	(36.6M)	(38.2M)	(42.2M)	(43.0M)	(43.3M)	(41.1M)
Accounts Payable	640.3K	1.3M	602.0K	817.9K	416.0K	472.3K
Cash	23.9K	34.4K	221.2K	413.0K	59.2K	56.2K
Non Current Assets Total	272.2K	235.3K	198.8K	162.5K	125.7K	119.4K
Cash And Short Term Investments	52.7K	51.6K	238.4K	430.3K	76.4K	72.6K
Net Receivables	51.9K	63.6K	61.2K	82.2K	38.0K	39.0K
Common Stock Shares Outstanding	24.1M	27.0M	32.5M	37.8M	59.2M	62.2M
Liabilities And Stockholders Equity	505.5K	421.0K	591.8K	798.2K	287.8K	273.4K
Other Stockholder Equity	4.6M	4.6M	5.1M	5.4M	5.6M	5.6M
Total Liab	4.9M	5.5M	7.4M	6.7M	4.8M	5.1M
Total Current Assets	233.2K	185.7K	393.0K	635.7K	162.1K	154.0K
Short Term Debt	449.3K	47.3K	611.4K	689.3K	813.2K	853.8K
Common Stock	27.5M	28.5M	30.3M	31.7M	33.1M	20.0M
Other Current Liab	107.3K	517.8K	106.6K	211.8K	239.5K	432.0K
Other Assets	266.2K	230.8K	195.5K	1.0	1.15	1.09
Non Current Liabilities Total	3.4M	3.2M	5.8M	4.6M	3.0M	2.1M
Other Current Assets	128.7K	70.5K	93.4K	123.2K	47.7K	89.2K
Net Tangible Assets	(1.9M)	(4.4M)	(5.1M)	(6.8M)	(6.2M)	(5.9M)
Property Plant Equipment	8.2K	6.0K	4.4K	3.3K	2.9K	2.8K
Net Invested Capital	(2.9M)	(5.0M)	(6.8M)	(5.9M)	(5.3M)	(5.6M)
Net Working Capital	(1.2M)	(2.1M)	(1.3M)	(1.4M)	(1.3M)	(1.4M)
Capital Stock	29.0M	28.5M	30.3M	31.7M	36.4M	32.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RepliCel Stock Analysis

When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC